Clinical Presentation, Risk Factors, and Outcomes of Hematogenous Prosthetic Joint Infection in Patients with Staphylococcus aureus Bacteremia

Abstract

Prosthetic joint infection is frequent in patients with existing arthroplasties and concomitant S. aureus bacteremia, particularly with community-acquired S. aureus bacteremia and multiple prostheses. In contrast, occult S. aureus prosthetic joint infection without clinical features suggestive of prosthetic joint infection at the time of S. aureus bacteremia is rare.

The use of rifampin in staphylococcal orthopaedic-device-related infections

“…In contrast, the risk of ODRI is markedly lower following hospital-acquired S.aureus bacteraemia [2]. This points towards the importance of early anti-staphylococcal treatment, since the duration of bacteraemia prior to antimicrobial treatment is generally longer in community-acquired than in hospital-acquired sepsis.…”

Virus-Derived Peptides for Clinical Applications

“…161 This pathogen is one of the major causes of wound infections and also arises as a complication during transfusion medicine techniques. 162 Existing methods for rapid detection are mainly reliant on antibodies and bioprobes, which can be tedious and expensive while having unintended cross-reactions.…”

Mouse model of hematogenous implant-related Staphylococcus aureus biofilm infection reveals therapeutic targets

“…Most PJI and other implant-related infections are thought to occur by invading bacteria during surgery or in the immediate postoperative period (7,8). However, hematogenous infections, which represent up to 20% of PJI, are especially problematic because they can occur at any time after implantation by bacteria from a remote source of infection or exposure seeding a previously well-functioning prosthesis through the bloodstream (9)(10)(11). Staphylococcus aureus is a particularly clinically relevant pathogen because it is the most common cause of PJI in humans (12,13), and S. aureus bacteremia results in a hematogenous PJI in 30-40% of patients with joint prostheses in place at the time of S. aureus bacteremia (9,11,14).…”

“…However, hematogenous infections, which represent up to 20% of PJI, are especially problematic because they can occur at any time after implantation by bacteria from a remote source of infection or exposure seeding a previously well-functioning prosthesis through the bloodstream (9)(10)(11). Staphylococcus aureus is a particularly clinically relevant pathogen because it is the most common cause of PJI in humans (12,13), and S. aureus bacteremia results in a hematogenous PJI in 30-40% of patients with joint prostheses in place at the time of S. aureus bacteremia (9,11,14). Furthermore, community-associated methicillin-resistant S. aureus (CA-MRSA) clinical isolates are increasingly becoming resistant to antibiotics (15,16), underscoring the unmet clinical need for therapeutic alternatives to conventional antibiotics.…”